Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • Fzd8-Fc: Phase Ib started

    OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Product: Fzd8-Fc (OMP-54F28) Business: Cancer Molecular target: NA Description: Wnt signaling antagonist Indication: First-line treatment of locally …

    Published on 2/24/2014
  • Fzd8-Fc: Phase Ib started

    OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Product: Fzd8-Fc (OMP-54F28) Business: Cancer Molecular target: NA Description: Wnt signaling antagonist Indication: Treat recurrent platinum-sensitive …

    Published on 2/24/2014
  • GLPG0974: Completed Phase IIa enrollment

    Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium Product: GLPG0974 Business: Autoimmune Molecular target: Free fatty acid receptor 2 (FFAR2) (GPR43) Description: Small molecule inhibitor of free fatty acid …

    Published on 2/24/2014
  • ItMSCs: Phase IIa started

    Stemedica Cell Technologies Inc., San Diego, Calif. Product: ItMSCs Business: Cardiovascular Molecular target: NA Description: Transplanted ischemic-tolerant mesenchymal stem cells Indication: Treat acute myocardial …

    Published on 2/24/2014
  • ItMSCs: Phase III started

    Stemedica Cell Technologies Inc., San Diego, Calif. Product: ItMSCs Business: Cardiovascular Molecular target: NA Description: Transplanted ischemic-tolerant mesenchymal stem cells Indication: Treat acute myocardial …

    Published on 2/24/2014
  • L-DOS47: Phase I/II ongoing

    Helix BioPharma Corp. (TSX:HBP), Aurora, Ontario Product: L-DOS47 Business: Cancer Molecular target: Not available Description: Plant-derived urease combined with a highly specialized antibody agent to identify lung …

    Published on 2/24/2014
  • Mepolizumab: Phase III started

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Mepolizumab (Bosatria) (SB-240563) Business: Inflammation Molecular target: Interleukin-5 (IL-5) Description: Humanized IgG mAb against IL-5 Indication: …

    Published on 2/24/2014
  • Nerventra laquinimod: Phase III discontinued

    Active Biotech AB (SSE:ACTI), Lund, Sweden Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Product: Nerventra laquinimod (SAIK-MS) Business: Autoimmune Molecular target: S100 calcium binding protein…

    Published on 2/24/2014
  • OMS824: Phase II started

    Omeros Corp. (NASDAQ:OMER), Seattle, Wash. Product: OMS824, OMS643762 Business: Neurology Molecular target: Phosphodiesterase-10 (PDE-10) Description: Selective inhibitor of phosphodiesterase-10 (PDE-10) Indication: …

    Published on 2/24/2014
  • ONT-380: Phase Ib started

    Array BioPharma Inc. (NASDAQ:ARRY), Boulder, Colo. Oncothyreon Inc. (NASDAQ:ONTY), Seattle, Wash. Product: ONT-380, ARRY-380 Business: Cancer Molecular target: Epidermal growth factor receptor 2 (EGFR2) (HER2) (ErbB2) (…

    Published on 2/24/2014
  • PRO 140: Phase IIb start

    CytoDyn Inc. (OTCBB:CYDY), Vancouver, Wash. Product: PRO 140 Business: Infectious Molecular target: CC chemokine receptor 5 (CCR5) (CD195) Description: Humanized mAb against CC chemokine receptor 5 (CCR5) Indication: …

    Published on 2/24/2014
  • RGI-2001: Phase I/II ongoing

    Regimmune Corp., Tokyo, Japan Product: RGI-2001 (formerly ToleroVax) Business: Transplant Molecular target: Natural killer T cells Description: Liposomal formulation of KRN7000, a synthetic derivative of alpha-…

    Published on 2/24/2014
  • Stivarga regorafenib: Phase III started

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Stivarga regorafenib (fluoro-sorafenib) (BAY 73-4506) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2); …

    Published on 2/24/2014
  • Subcutaneous C1-INH: Phase III started

    CSL Ltd. (ASX:CSL), Melbourne, Australia Product: Subcutaneous C1-INH Business: Inflammation Molecular target: Complement 1 (C1) esterase Description: Complement 1 (C1) esterase inhibitor Indication: Prevent hereditary …

    Published on 2/24/2014
  • Amikacin Fosfomycin Inhalation System: Phase II started

    Cardeas Pharma Corp., Seattle, Wash. Product: Amikacin Fosfomycin Inhalation System Business: Infectious Molecular target: NA Description: Inhalation solution of the antibiotics amikacin and fosfomycin Indication: Treat…

    Published on 1/20/2014
  • Ampion: Phase III started

    Ampio Pharmaceuticals Inc. (NYSE-M:AMPE), Greenwood Village, Colo. Product: Ampion Business: Autoimmune Molecular target: NMDA receptor; Serotonin (5-HT2C) receptor Description: A cyclic aspartate-alanine dipeptide …

    Published on 1/20/2014
  • Blinatumomab: Phase III started

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Product: Blinatumomab (AMG 103) (formerly MT103) Business: Cancer Molecular target: CD19 Description: Bispecific T cell engager (BiTE) against CD19 Indication: Treat newly…

    Published on 1/20/2014
  • CVT-301: Completed Phase IIb enrollment

    Civitas Therapeutics Inc., Chelsea, Mass. Product: CVT-301 Business: Neurology Molecular target: NA Description: Inhaled formulation of levodopa delivered via Civitas' Arcus inhalation technology Indication: Treat motor…

    Published on 1/20/2014
  • Cytori Cell Therapy: Phase II start

    Cytori Therapeutics Inc. (NASDAQ:CYTX; Xetra:XMPA), San Diego, Calif. Product: Cytori Cell Therapy (adipose-derived regenerative cells) (ADRCs) Business: Musculoskeletal Molecular target: Not available Description: …

    Published on 1/20/2014
  • DEZ-001: Completed Phase IIb enrollment

    Dezima Pharma B.V., Naarden, the Netherlands Mitsubishi Tanabe Pharma Corp. (Tokyo:4508), Osaka, Japan Product: DEZ-001 (formerly TA-8995) Business: Endocrine/Metabolic Molecular target: Cholesteryl ester transfer …

    Published on 1/20/2014
  • EDP-788: Phase I started

    Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), Watertown, Mass. Product: EDP-788 Business: Infectious Molecular target: NA Description: Prodrug of EDP-322, a bicyclolide antibiotic product Indication: Treat methicillin-…

    Published on 1/20/2014
  • Nefecon: Completed Phase IIb enrollment

    Archimedes Pharma Ltd., Reading, U.K. Pharmalink AB, Stockholm, Sweden Product: Nefecon (PL-56) Business: Renal Molecular target: NA Description: Enteric formulation of a locally acting corticosteroid that downregulates…

    Published on 1/20/2014
  • NIRsupreme Ridaforolimus-Eluting Coronary Stent System: Phase II started

    Medinol Ltd., Tel Aviv, Israel Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Cambridge, Mass. Product: NIRsupreme Ridaforolimus-Eluting Coronary Stent System Business: Cardiovascular Molecular target: NA Description: Cobalt…

    Published on 1/20/2014
  • NIRsupreme Ridaforolimus-Eluting Coronary Stent System: Phase II started

    Medinol Ltd., Tel Aviv, Israel Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Cambridge, Mass. Product: NIRsupreme Ridaforolimus-Eluting Coronary Stent System Business: Cardiovascular Molecular target: NA Description: Cobalt…

    Published on 1/20/2014
  • NKTR-102: Phase III ongoing

    Nektar Therapeutics (NASDAQ:NKTR), San Francisco, Calif. Product: NKTR-102 (etirinotecan pegol) Business: Cancer Molecular target: Topoisomerase I (TOP1) Description: Topoisomerase I (TOP1) inhibitor-polymer conjugate …

    Published on 1/20/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993